BioAdaptives, Inc. (OTC: BDPT) detailed the scientific strategy behind its Xcellara cellular wellness platform, ahead of the planned Aug. 1 commercial launch of XcellaraHeart. The platform combines a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body's natural signaling pathways and direct those cells to targeted areas.
XcellaraHeart, the platform's first commercial application, pairs the Xcellara base with Tanshinone IIA, a Danshen-derived compound studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives said it plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness and metabolic resilience using the same supply-and-direction development model. The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science, separating what has been demonstrated in BioAdaptives' human clinical research on the Xcellara base from published research on Tanshinone IIA and from the Company's product-development rationale for combining the two.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The Company's flagship Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com.
This announcement is significant as it marks a strategic pivot from a single supplement to a platform approach, potentially expanding the company's addressable market. The Xcellara platform's ability to mobilize stem cells and direct them to specific tissues could have broad implications for wellness and age-related health concerns. The company's focus on evidence-based science, including a human clinical trial for the base formula, may differentiate it in the dietary supplement market, which often lacks rigorous scientific backing. However, the company notes that the dossier separates clinical evidence from product rationale, indicating a clear distinction between proven and hypothesized benefits.
The planned expansion into multiple wellness categories suggests BioAdaptives is positioning Xcellara as a versatile platform, which could attract a wider consumer base interested in targeted health support. The success of XcellaraHeart will be a key indicator of market acceptance for the platform model.
